A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis 
      This Phase 3 study is intended to provide evidence of the efficacy and safety of CP 690,550
      when dosed 5 mg and 10 mg twice a day as monotherapy in adult patients with moderate to
      severe Rheumatoid Arthritis. It is intended to confirm the benefits of CP-690,550 in
      improving signs and symptoms and physical function that were observed in the Phase 2
      Rheumatoid Arthritis studies.
     Arthritis, Rheumatoid :

          -  The patient has a diagnosis of RA based upon the American College of Rheumatology
             (ACR) 1987 Revised Criteria.

          -  The patient has active disease at both Screening and Baseline, as defined by both: ≥6
             joints tender or painful on motion; and ≥6 joints swollen; and fulfills 1 of the
             following 2 criteria at Screening: 1.ESR (Westergren method) >28 mm in the local
             laboratory. 2. CRP >7 mg/L in the central laboratory

          -  Patient had an inadequate response to at least one DMARD (traditional or biologic) due
             to lack of efficacy or toxicity.

          -  No evidence of active or latent or inadequately treated infection with Mycobacterium
             tuberculosis.

          -  Patient has washed out of all DMARDs other that antimalarials

         :

          -  Blood dyscrasias including confirmed: 1. Hemoglobin <9 g/dL or Hematocrit <30%; 2.
             White blood cell count <3.0 x 109/L; 3. Absolute neutrophil count <1.2 x 109/L; 4.
             Platelet count <100 x 109/L

          -  History of any other autoimmune rheumatic disease other than Sjogren's syndrome

          -  No malignancy or history of malignancy.

          -  History of infection requiring hospitalization, parenteral antimicrobial therapy, or
             as otherwise judged clinically significant by the investigator, within the 6 months
             prior to the first dose of study drug
      